Optimi Health (TSE:OPTI) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Optimi Health Corp. and Psyence Biomedical Ltd. have announced their intention to partner, with Optimi set to become the exclusive supplier of GMP nature-derived psilocybin extract for Psyence’s FDA-approved palliative care therapies. The collaboration aims to support Psyence’s clinical trials and regulatory submissions in advancing psilocybin-based mental health treatments. While the letter of intent is non-binding, the successful execution of a binding agreement could lead to transformative treatments within the palliative care sector.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
